Hepatocellular carcinoma associated with membranous obstruction of the inferior vena cava: Incidence, characteristics, and risk factors and clinical efficacy of tace

Radiology

Volumn 254, Issue 2, 2010, Pages 617-626

  Gwon, Dong Il ^a   Ko, Gi Young ^a   Yoon, Hyun Ki ^a   Sung, Kyu Bo ^a   Kim, Jin Hyoung ^a   Lee, Seung Soo ^a   Lee, Jae Myeong ^a   Ohm, Joon Young ^a   Shin, Ji Hoon ^a   Song, Ho Young ^a  

^a University of Ulsan College of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLAN; CISPLATIN; GADOLINIUM; GADOLINIUM PENTETATE; IODINATED POPPYSEED OIL; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; AGED; ARTICLE; BUDD CHIARI SYNDROME; CANCER INCIDENCE; CANCER SURVIVAL; CHEMOEMBOLIZATION; COMPUTER ASSISTED TOMOGRAPHY; DOPPLER FLOWMETER; ECHOGRAPHY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; INFERIOR CAVA VEIN; INFERIOR CAVA VEIN OBSTRUCTION; INFERIOR VENACAVOGRAPHY; INFORMED CONSENT; LIVER CELL CARCINOMA; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; RISK FACTOR; THERAPY EFFECT; TREATMENT OUTCOME; DIAGNOSTIC IMAGING; INCIDENCE; LIVER TUMOR; MIDDLE AGED; PATHOLOGY; RETROSPECTIVE STUDY; SEX DIFFERENCE; SURVIVAL RATE;

BUDD-CHIARI SYNDROME; CARCINOMA, HEPATOCELLULAR; CHEMOEMBOLIZATION, THERAPEUTIC; DIAGNOSTIC IMAGING; FEMALE; HUMANS; INCIDENCE; LIVER NEOPLASMS; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; RISK FACTORS; SEX FACTORS; SURVIVAL RATE; VENA CAVA, INFERIOR;

EID: 77449145134     PISSN: 00338419     EISSN: 15271315     Source Type: Journal    
DOI: 10.1148/radiol.09090738     Document Type: Article

References (40)

1. Okuda K, Kage M, Shrestha SM. Proposal of a new nomenclature for Budd-Chiari syndrome: hepatic vein thrombosis versus thrombosis of the inferior vena cava at its hepatic portion. Hepatology 1998;28:1191-1198.
2. Janssen HL, Garcia-Pagan JC, Elias E, et al. Budd-Chiari syndrome: a review by an expert panel. J Hepatol 2003;38:364-371.
3. Valla DC. The diagnosis and management of the Budd-Chiari syndrome: consensus and controversies. Hepatology 2003;38:793-803.
4. Takeuchi J, Takada A, Hasumura Y, Matsuda Y, Ikegami F. Budd-Chiari syndrome associated with obstruction of the inferior vena cava. Am J Med 1971;51:11-20.
5. Espana P, Figuera D, Femadez de Miguel JM, Anaya A, Menendez J, Durantez A. Membranous obstruction of the inferior vena cava and hepatic veins. Budd-Chiari syndrome? - a treatable disease. Am J Gastroenterol 1980;73:28-32.
6. Kew MC, McKnight A, Hodkinson J, Bukofzer S, Esser JD. The role of membranous obstruction of the inferior vena cava in the etiology of hepatocellular carcinoma in southern African blacks. Hepatology 1989;9:121-125.
7. Simson IW. Membranous obstruction of the inferior vena cava and hepatocellular carcinoma in South Africa. Gastroenterology 1982;82:171-178.
8. Kage M, Arakawa M, Kojiro M, Okuda K. Histopathology of membranous obstruction of the inferior vena cava in the Budd-Chiari syndrome. Gastroenterology 1992;102:2081-2090.
9. Okuda H, Yamagata H, Obata H, et al. Epidemiological and clinical features of Budd-Chiari syndrome in Japan. J Hepatol 1995;22:1-9.
10. Nakamura T, Nakamura S, Aikawa T, Suzuki O, Onodera A, Karoji N. Obstruction of the inferior vena cava in the hepatic portion and hepatic vein: report of 18 cases and review of the Japanese literature. Angiology 1968;19:479-498.
11. Dilawari JB, Mambery P, Chawla Y, et al. Hepatic venous flow obstruction (Budd-Chiari syndrome): experience with 177 patients and a review of the literature. Medicine (Baltimore) 1994;73:21-36.
12. Shrestha SM, Okuda K, Uchida T, et al. Epidemicity and clinical picture of liver disease due to obstruction of the hepatic portion of the inferior vena cava in Nepal. J Gastroenterol Hepatol 1996;11:170-179.
13. Matsui S, Ichida T, Watanabe M, et al. Clinical features and etiology of hepatocellular carcinoma arising in patients with membranous obstruction of the inferior vena cava: in reference to hepatitis viral infection. J Gastroenterol Hepatol 2000;15:1205-1211.
14. Moucari R, Rautou PE, Cazals-Hatem D, et al. Hepatocellular carcinoma in Budd-Chiari syndrome: characteristics and risk factors. Gut 2008;57:828-835.
15. Llovet JM, Real MI, Montana X, et al. Arterial embolisation or chomoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomized controlled trial. Lancet 2002;359:1734-1739.
16. Lo CM, Ngan H, Tso WK, et al. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 2002;35:1164-1171.
17. Shin SH, Chung YH, Suh DD, et al. Characteristic clinical features of hepatocellular carcinoma associated with Budd-Chiari syndrome: evidence of different carcinogenic process from hepatitis B virus-associated hepatocellular carcinoma. Eur J Gastroenterol Hepatol 2004;16:319-324.
18. Park JO, Lee SI, Song SY, et al. Measuring response in solid tumors: comparision of RECIST and WHO response criteria. Jpn J Clin Oncol 2003;33:533-537.
19. Georgiades CS, Hong K, D'Angelo M, Geschwind JF. Safety and efficacy of transarterial chemoembolization in patients with unresectable hepatocellular carcinoma and portal vein thrombosis. J Vasc Interv Radiol 2005;16:1653-1659.
20. Brown DB, Gould JE, Gervais DA, et al. Transcatheter therapy for hepatic malignancy: standardization of terminology and reporting criteria. J Vasc Interv Radiol 2007;18:1469-1478.
21. Wanless IR. Regenerative nodules in Budd-Chiari syndrome. Hepatology 1994;19:1391.
22. Vilgrain V, Lewin M, Vons C, et al. Hepatic nodules in Budd-Chiari syndrome: imaging features. Radiology 1999;210:443-450.
23. Tanaka M, Wanless IR. Pathology of the liver in Budd-Chiari syndrome: portal vein thrombosis and the histogenesis of venocentric cirrhosis, veno-portal cirrhosis, and large regenerative nodules. Hepatology 1998;27:488-496.
24. Fattovich G, Stroffolini T, Zagni I, Donato F. Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology 2004;127:S35-S50.
25. Kawaguchi T, Sata M, Ono N, et al. Budd-Chiari syndrome complicated by hepatocellular carcinoma with no evidence of infection with hepatitis virus: a case report. Hepatogastroenterology 1999;46:3237-3240.
26. Takayasu K, Muranatsu Y, Moriyama N, et al. Radiological study of idiopathic Budd-Chiari syndrome complicated by hepatocellular carcinoma: a report of four cases. Am J Gastroenterol 1994;89:249-253.
27. Takamura M, Ichida T, Yokoyama J, Matsuda Y, Nomoto M, Aoyagi Y. Recurrence of hepatocellular carcinoma 102 months after successful eradication and removal of membranous obstruction of the inferior vena cava. J Gastroenterol 2004;39:681-684.
28. Bruix J, Sherman M, Llovet JM, et al. Clinical management of hepatocellular carcinoma: conclusions of the Barcelona-2000 EASL conference. J Hepatol 2001;35:421-430.
29. Chen MF, Hwang TL, Jeng LB, Wang CS, Jan YY, Chen SC. Postoperative recurrence of hepatocellular carcinoma: two hundred five consecutive patients who underwent hepatic resection in 15 years. Arch Surg 1994;129:738-742.
30. Imamura H, Matsuyama Y, Tanaka E, et al. Risk factors contributing to early and late phase intrahepatic recurrence of hepatocellular carcinoma after hepatectomy. J Hepatol 2003;38:200-207.
31. Okuda K, Ohtsuki T, Obata H, et al. Natural history of hepatocellular carcinoma and prognosis in relation to treatment: study of 850 patients. Cancer 1985;56:918-928.
32. Llovet JM, Bru C, Bruix J. Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis 1999;19:329-338.
33. Prospective validation of the CLIP score: a new prognostic system for patients with cirrhosis and hepatocellular carcinoma. The Cancer of the Liver Italian Program (CLIP) Investigators. Hepatology 2000;31:840-845.
34. Kudo M, Chung H, Haji S, et al. Validation of a new prognostic staging system for hepatocellular carcinoma: the JIS score compared with the CLIP score. Hepatology 2004;40:1396-1405.
35. Park KW, Park JW, Choi JI, et al. Survival analysis of 904 patients with hepatocellular carcinoma in a hepatitis B virusendemic area. J Gastroenterol Hepatol 2008;23:467-473.
36. Ebied OM, Federle MP, Carr BI, et al. Evaluation of responses to chemoembolization in patients with unresectable hepatocellular carcinoma. Cancer 2003;97:1042-1050.
37. Bruix J, Sala M, Llovet JM. Chemoembolization for hepatocellular carcinoma. Gastroenterology 2004;127:S179-S188.
38. Takayasu K, Arii S, Ikai I, et al. Prospective cohort study of transarterial chemoembolization for unresectable hepatocellular carcinoma in 8510 patients. Gastroenterology 2006;131:461-469.
39. Hatanaka Y, Yamashita Y, Takahashi M, et al. Unresectable hepatocellular carcinoma: analysis of prognostic factors in transcatheter management. Radiology 1995;195:747-752.
40. Savastano S, Miotto D, Casarrubea G, Teso S, Chiesura-Corona M, Feltrin GP. Transcatheter arterial chemoembolization for hepatocellular carcinoma in patients with Child's grade A or B cirrhosis: a multivariate analysis of prognostic factors. J Clin Gastroenterol 1999;28:334-340.